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Signs and Symptoms 
Malignant hyperthermia is an autosomal dominant disorder with variable 
penetrance.  It is a genetic disorder of the skeletal muscle affecting a mutation 
of the ryanodine receptor.  This receptor is found on the endoplasmic 
reticulum and is the major calcium release channel of skeletal muscles.  
Individuals with malignant hyperthermia have an environmental agent, usually 
succinylcholine or other inhaled anesthetics, that triggers the inappropriate 
release of calcium into skeletal muscles.  This increase in intracellular calcium 
causes muscle contraction.  With the increase in calcium, muscles attempt to 
normalize the calcium with mechanisms that require energy which can 
increase "muscle metabolism two to three fold"(Nagelhout, p 830, 2014).  
When the overactive muscle metabolism oxygen consumption is increased, ATP 
is depleted, and carbon dioxide is increased.  This nefarious cycle leads to lactic 
acid production and subsequently acidosis, hyperthermia, and cell destruction.  
With myocyte failure, potassium, myoglobin, and creatine kinase leak into the 
circulation.  The fact that skeletal muscle accounts for forty to fifty percent of 
our body mass explains the often devastating systemic effects malignant 
hyperthermia can have on patients (Brislin, 2013). 
Malignant hyperthermia, though 
uncommon, is a serious and life 
threatening condition.  Malignant 
hyperthermia is an autosomal dominant 
disorder that affects skeletal muscle.  It 
can be caused by various general 
anesthetic agents like succinylcholine and 
several inhaled anesthetics.  Malignant 
hyperthermia is a relevant topic to 
certified registered nurse anesthetists 
due to the potentially fatal result if not 
recognized and treated promptly.  In 
understanding the pathophysiology, risk 
factors, signs and symptoms, 
epidemiology, and current treatments the 
health care provider can help to prevent 
complications due to this disorder 
(Nagelhout, 2014). 
Malignant hyperthermia has a wide range 
of manifestations in a patient.  It can be 
very acute with sudden and apparent 
muscle rigidity post anesthetic or the 
process can occur gradually and not show 
signs or symptoms until several hours post 
procedure.    Besides the variety of timing, 
malignant hyperthermia also varies in 
severity from mild complications to full 
systemic complications that can result in 
patient death.  Typically, malignant 
hyperthermia begins when a genetically 
susceptible individual undergoes 
anesthesia, usually succinylcholine, 
desflurane, or sevoflurane.  The best initial 
indicator of malignant hyperthermia is a 
rise in end tidal carbon dioxide unrelated to 
how well the patient is ventilating.  Other 
important signs are tachycardia, tachypnea, 
arrythmias, and labile blood pressure.  
Muscle rigidity occurs seventy five percent 
of the time with malignant hyperthermia.  
Although hyperthermia is in the name of 
this complication, it is often a late sign.  
Decreased SaO2 is observed and dark 
colored urine from myoglobinuria can be 
noted.  Laboratory findings consistent with 
an malignant hyperthermia diagnosis are 
an elevated CO2,  base deficit, pH<7.25, 
serum K greater than 6meq/l, creatine 
kinase greater than 20,000 units/ml, serum 
myogolbin greater than 170mcg/L, and 
urine myoglobin greater than 60mcg/L 
(Mitchell-Brown, 2013). 
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Malignant hyperthermia is a genetically acquired disease that can cause 
death if not diagnosed and treated early enough.  It's detrimental effects 
depend greatly on the practitioners knowledge and understanding of the 
pathophysiologic process and the signs and symptoms that manifest with 
malignant hyperthermia.  Once diagnosis is determined treatment should 
be given immediately to best prevent ill outcomes brought on by malignant 
hyperthermia. 
Conclusion 
Malignant hyperthermia is a rare disorder and can often have devastating effects.  It 
is often a difficult disease to diagnose due to other diseases with similar symptoms and 
the fact that malignant hyperthermia can happen at different times during the procedure.  
Understanding pathophysiology of this disorder can lead to better outcomes and prevent 
catastrophic events.   With early recognition, diagnosis, and treatment with dantrolene 
sodium the mortality rate of malignant hyperthermia decreased from 80% in the 1970s 
to less than 5% by 2007(Dirksen, 2013).   
 
Significance of Pathophysiology 
The understanding of the pathophysiology and signs and symptoms of 
malignant hyperthermia directly affects nursing care.  It is important to 
understand what population makes up high risk patients.  A practitioner, with a 
good preoperative history, can ascertain if a person is a high risk.  Any person with 
a family history of anesthetic reaction or malignant hyperthermia should be red 
flagged and suspected of possibly getting malignant hyperthermia with anesthesia.   
Also, the practitioner knows that the highest rate of malignant hyperthermia occurs 
amongst younger people with an average age of 18.   A practitioner should also 
know to correctly diagnose and know the steps to handle a malignant 
hyperthermic crisis.  The Malignant Hyperthermia Association of the United States 
recommends that information on how to handle a crisis be posted in all surgical 
rooms.  The steps include to discontinue anesthetics if possible, hyperventilate 
with 100% FiO2, give dantrolene sodium, treat fever aggressively, and correct 
arrhythmias with treatment of acidosis and electrolyte abnormalities.  Dantrolene 
is an important medication in malignant hyperthermia and has been directly 
related to the drop in mortality in the last 30 years.  Dantrolene relaxes muscles by 
decreasing calcium produced by sarcoplasmic reticulum which directly reverses 
the pathophysiologic process of malignant hyperthermia(Donnelly, 1994). 
Environmental Agent 
(Anesthetic Agent) 
Increase Release of 
Calcium into Muscle 
Increase Muscle 
Metabolism 
Increase O2 Consumption 
• Increase CO2 
• Increase Lactic Acid 
• Hyperthermia 
Myocyte Failure/Death 
Increase Potassium, 
Myoglobin, Creatine 
Kinase 
Arrythmias, Kidney 
Failure, Metabolic 
Acidosis, Cellular Death 
Stop Surgery if possible and 
discontinue anesthetic agents 
Initiate Malignant hypertensive 
response team 
Given Dantrolene 2.5mg/kg 
(repeat as needed) 
Hyperventilate and give 100% 
FiO2 
Obtain blood gas and labs 
Cool Patient if core 
temperature>39C 
Correct electrolytes and blood 
gas (hyperkalemia, metabolic 
acidosis) 
Stability Indicators 
1. ETCO2 normal 
2. HR stabilized 
3. Hyperthermia resolved 
4. Muscle rigidity resolved 
Treatment Pathway 
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